ساركوما إيوينج المصحوبة بنقائل رئوية عند التشخيص

References

DOI: 10.1016/j.annonc.2021.08.1995

• Approximately 25% of patients are diagnosed with metastatic disease (10%: lung; 10%: bones/bone marrow; 5%: combinations or others).
• Patients with metastases at diagnosis are treated with the same treatment approach as patients with localised disease, but have a worse prognosis.
• The interval-compressed VDC/IE regimen showed superiority to VIDE for both event-free survival and OS, with similar toxicity, and it is currently the preferred first-line treatment in ES [I, B].
• Local treatment, especially in the presence of responding metastatic disease, has been proved to be associated with outcome improvement, and should therefore be attempted [II, B].
• Whole-lung irradiation, particularly when achieving complete remission of all lung metastases, can be used in this setting, although data demonstrating an improvement in outcome are lacking [III, C].
• Recent studies suggest that 100% response is most optimal to define a good tumour response in ES.
• Change in the size of the soft tissue mass is easily evaluated on MRI, a good predictor of tumour response.